Ark Healthcare Pioneers AI-Driven Innovation in China's $474B Weight Management Market Serving Over 400 Million People

This September, Hangzhou First People's Hospital reported that it had admitted a special patient, “A Fang”—

To lose weight, Afang purchased “Bigu Energy Pills” online and survived for several consecutive days by consuming only 2,000 ml of water and taking one energy pill daily. After experiencing the initial joy of losing 5 kilograms in the first 7 days, she began to feel unwell. By the 20th day, she developed a high fever of 39°C and lapsed into a coma, prompting her family to rush her to the hospital. Afang was subsequently diagnosed with sepsis.

Although this is an isolated case, unhealthy weight-loss practices such as blind fasting and excessive training are undermining people’s physical health, with similar incidents occurring repeatedly. Behind the chaos in the weight-loss industry lie widespread anxiety about body weight and a massive demand for weight reduction. According to a study based on the Global Burden of Disease 2021 (GBD 2021) data published in March 2025 by The Lancet, a leading international medical journal, China had become the country with the largest number of overweight and obese individuals worldwide in 2021, totaling 402 million people. This figure is projected to rise to 627 million by 2050.

The “Chinese Guidelines for Medical Nutrition Therapy of Overweight/Obesity (2021)” point out that “multiple surveys have shown more than 200 obesity-related comorbidities, and even modest weight loss can improve these comorbidities.” Scientific weight management is becoming increasingly important.

In light of this, a series of national-level policies have been intensively introduced. The “Implementation Plan for the ‘Weight Management Year’ Campaign” (Guo Wei Yi Ji Fa [2024] No. 21), jointly formulated by 16 departments including the National Health Commission, proposes that starting from 2024, China will strive to establish widespread supportive environments for weight management, significantly enhance public awareness and skills in weight management, and promote healthier lifestyles over a period of approximately three years. In April 2025, the National Patriotic Health Campaign Committee further issued a notice incorporating actions such as healthy weight management into the Healthy China Initiative, thereby elevating weight management from an individual health behavior to a key issue in national public health governance.

However, as policies are steadily advanced, the industry still faces a series of challenges. For instance, the unequal allocation of medical resources between urban and rural areas has significantly affected the accessibility of weight management interventions; the lack of established mechanisms has resulted in insufficient sustainability of behavioral interventions; and technological applications continue to encounter translation bottlenecks due to various constraints.

In this context,Guided by the China Association for Quality and Safety Promotion of Food and Drug Enterprises and hosted by its Food Safety Working Committee, the Industry Collaborative Innovation Symposium on “Healthy China: Pioneering AI-Enabled Weight Management” was recently held at the National People’s Congress Conference Center. Attendees included Academician Chen Runsheng, Member of the Chinese Academy of Sciences and the International Eurasian Academy of Sciences, Researcher and Doctoral Supervisor at the Institute of Biophysics, Chinese Academy of Sciences; Academician Ren Fazheng, Member of the Chinese Academy of Engineering, Professor and Doctoral Supervisor at the College of Food Science and Nutritional Engineering, China Agricultural University; as well as numerous other experts, scholars, frontline clinical practitioners, and corporate representatives.

This conference not only issued a call to society for “scientific weight loss,” but also demonstrated that the methodology for “sustainable innovation” in the current weight management industry is gradually taking shape.

Inter-individual variations in overweight/obesity arise from differences in genetic makeup, lifestyle, and physiological status. Traditional weight management approaches struggle to achieve sustained, effective weight loss due to issues such as “one-size-fits-all” interventions, delayed feedback, and low user adherence.

Personalized intervention strategies based on big data and AI leverage data-driven precise behavioral classification to overcome the limitations of traditional “one-size-fits-all” approaches, demonstrating superior performance in weight loss efficiency, body composition optimization, and user adherence. Meanwhile, by establishing a technological framework of “data acquisition–pattern recognition–precise intervention,” intelligent weight management can be more effectively realized.

Both domestic and international enterprises are exploring the integration of AI technologies to transform traditional weight management paradigms.

In the United States, the weight loss sector has seen the emergence of Noom, a unicorn valued at $27 billion. Noom’s development model offers valuable insights for the industry: First, it leverages AI technology to create 3D avatars following full-body scans, enabling users to gain a more intuitive understanding of their physical condition. Second, it generates personalized health reports tailored to users based on big data from the U.S. population, and employs AI coaches to deliver personalized behavioral interventions through daily user interactions and feedback. Additionally, Noom incorporates human coaches to encourage and support behavioral changes. With the approval of semaglutide for weight management indications, Noom has rapidly integrated evidence-based clinical interventions to further assist users in managing their weight.

Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical, Was Invited to Attend and Deliver a Keynote Speech

In China, Fangzhou Pharmaceutical, a leading enterprise in AI-driven chronic disease management, is addressing key pain points in the weight loss sector—such as fragmented solutions, unsustainable results, and lack of safety guarantees—by developing an “AI + Weight Loss” digital intelligence solution.—Leveraging its resource and data advantages in the field of chronic disease management, Fangzhou Pharmaceutical uses its self-developed Xingshi Medical Large Model as the technological foundation. By connecting patients and healthcare providers through AI Doctor Assistants, AI Health Managers, and AI Medication Assistants, it applies AI technology throughout the entire weight loss service process. Specifically, users need only send their physical examination reports, BMI data, and related instructions to the AI Health Manager, which then integrates data such as age, weight, underlying conditions, and metabolic indicators via algorithms to generate personalized weight loss recommendations. For obese patients with medication needs, the platform’s AI Medication Assistant provides professional answers 24/7. When consultations involve complex medication requirements, the platform matches users with professional consultants who have medical backgrounds to provide explanations and follow-up care, ensuring that the medication process is safe and scientific. Compared to Noom’s online expansion approach, Fangzhou Pharmaceutical builds familiar doctor-patient relationships based on initial offline consultations, resulting in higher user trust in both the platform and its doctors.

Leading enterprises’ innovative explorations and implementation of their strategies are steering industry development and propelling weight management into the AI era.

The development and implementation of innovative AI-based weight management solutions are underpinned by clinical research and exploration conducted in academic medical institutions.

However, past clinical research innovation has faced numerous challenges.On one hand, inconsistencies in standards across clinical institutions may lead to the fragmentation of clinical research. On the other hand, from the perspective of researchers, primary care settings, despite having relatively weaker medical capabilities, possess more abundant data that remains underutilized and warrants better exploitation. Furthermore, regarding departmental coordination, the emergence of specialized weight-loss clinics has posed a significant challenge in effectively integrating various departments involved in weight management to facilitate interdisciplinary research.

At this conference, the establishment of a national-level academic exchange platform for weight management is poised to address the aforementioned challenges. Notably, Fangzhou Pharmaceutical has become one of the first corporate representatives to join this national academic exchange platform for weight management, leveraging its expertise in chronic diseases such as overweight and obesity, as well as its innovative “AI + Weight Management” solutions.

The establishment of a national-level academic exchange platform for weight management has also laid a stronger foundation for the future development of innovative AI-driven weight management solutions:

First, in terms of scientific research resources, the platform currently brings together numerous authoritative experts from China in the fields of weight loss, metabolic disease management, and nutrition. In the future, it is expected to promote interdisciplinary integration through in-depth discussions and exchanges on the latest clinical advances in the field of weight loss.

Second, in terms of clinical data, the establishment of data standards and the achievement of data interoperability are expected to further facilitate multi-center clinical studies by healthcare institutions in the future, including clinical cohort studies and randomized controlled trials, thereby helping to elevate the level of clinical research.

Third, in terms of scientific research talent, the platform will continue to carry out continuing medical education, further facilitate the development of talent echelons, address the historical weakness of grassroots research, and provide intellectual support for the advancement of clinical research;

Fourth, in the area of medical science popularization, the platform will further enhance public awareness of weight management and better serve the general public through initiatives such as science communication campaigns, health education programs, expert outreach clinics, and medical poverty alleviation efforts.

More importantly, with the establishment of national-level academic platforms for weight management and the participation of industry enterprises, an innovation-driven model characterized by “industry leaders guiding direction through innovative services—academic platforms facilitating innovative R&D” is further taking shape. This development is expected to accelerate the translation of innovative technologies into novel solutions for individuals with overweight or obesity.

However, it is evident that innovative technologies and solutions alone are insufficient. In the past, due to a lack of collaborative mechanisms, products from innovative enterprises in the field of AI-enabled weight management failed to integrate effectively with clinical institutions. As a result, even high-quality tools could not deliver greater benefits to patients, making it difficult for these companies to sustain their operations.

In the field of AI-driven weight management, beyond ensuring foundational innovations and leading the industry with innovative solutions, greater cross-industry collaboration is needed to accelerate the practical implementation of these innovations.

This requires joint efforts from regulatory authorities, academic institutions, and practitioners.

Currently, countries around the world are exploring and providing policy-level guidance. For instance, the UK’s National Health Service has established a national obesity database, offering free nutritional counseling, exercise guidance, and pharmacological treatment to high-risk patients through tiered management. Sweden has legislated the inclusion of obesity in its chronic disease registry system, mandating healthcare institutions to provide multidisciplinary consultation services. China has drawn upon advanced international experiences. For example, China’s first-ever Guidelines for the Diagnosis and Treatment of Obesity, released in 2024, referenced international standards to clarify clinical application and diagnostic and therapeutic norms for GLP-1 medications. Furthermore, the “Year of Weight Management” special campaign launched in 2024 defined the “four-party responsibilities” of the government, enterprises, schools, and individuals in weight management.

From a technical perspective, breakthroughs in intelligent and digital technologies have enabled precise phenotyping and dynamic intervention for patients with obesity. Meanwhile, the construction of innovative ecosystems such as Fangzhou Pharmaceutical’s “AI + H2H (Hospital to Home)” model is demonstrating greater efficacy in the disease management of overweight and obese populations by covering the entire disease lifecycle from in-hospital to out-of-hospital care.

“Healthy China • AI + Weight Management Pioneer” National Promotion Campaign Launch Ceremony

Policy, technology, and business models are all indispensable, as is the participation of regulatory authorities, academic institutions, and enterprises. Representatives from research institutes, clinical institutions, regulatory bodies, and the industry jointly participated in this conference to explore how to build a vibrant innovation ecosystem for AI-enabled weight management. The conference also launched the “Healthy China • AI + Weight Management Pioneer” national promotion campaign, issuing a call to all industry stakeholders to collaboratively build an ecosystem for “scientific weight loss.”

It undoubtedly aligns with the goals of “Building a Digital China.” On October 24, at a press conference to introduce and interpret the spirit of the Fourth Plenary Session of the 20th Central Committee of the Communist Party of China, Yin Hejun, Secretary of the Leading Party Members Group and Minister of the Ministry of Science and Technology, pointed out that efforts will be made to advance the construction of a Digital China in depth. This includes building an open, shared, and secure national integrated data market to promote the deep integration of the real economy and the digital economy; accelerating innovation in digital and intelligent technologies such as artificial intelligence, and strengthening the efficient supply of computing power, algorithms, and data; and comprehensively implementing the “AI+” initiative to empower all industries across the board.

The convening of the “Healthy China: AI + Weight Management Pioneer” conference demonstrates that a mechanism for “sustainable innovation” is being established in the field of AI-enabled weight management. This sustainable innovation mechanism—characterized by industry leaders such as Fangzhou Pharmaceutical driving frontier directions through innovative solutions, further safeguarding scientific research and innovation via national-level academic exchange platforms, and building an industrial ecosystem through multi-party collaborative mechanisms—will play a pivotal role in the AI + weight management sector. It will facilitate the emergence and clinical application of higher-quality solutions, bringing about genuine transformation to the industry.